Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178973 | 0.89 | MTNR1A (0.39) | MTNR1AAPPBACE1BACE2CNR2 | |
| SCHEMBL2177373 | 0.89 | THRB (0.39) | MTNR1AMAPK14 | |
| SCHEMBL2177969 | 0.88 | PLA2G4B (0.41) | MTNR1AMAPK14 | |
| SCHEMBL2177626 | 0.86 | NPC1 (0.43) | MTNR1AMAPK14 | |
| SCHEMBL2177091 | 0.85 | MTNR1A (0.41) | MTNR1A | |
| SCHEMBL2176423 | 0.85 | BACE1 (0.41) | APPBACE1BACE2MAPK14CNR2 | |
| SCHEMBL2178547 | 0.82 | MAPK14 (0.44) | MAPK14 | |
| SCHEMBL2177594 | 0.82 | SMPD1 (0.37) | APPBACE1BACE2CNR2 | |
| SCHEMBL2177685 | 0.82 | MTNR1A (0.39) | MTNR1AMAPK14 | |
| SCHEMBL2174497 | 0.81 | TSHR (0.43) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101282930-B | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS INC | 2012-10-24 | — | — | CN | claimed |
| CN-101282930-A | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS INC (KR) | 2008-10-08 | — | — | CN | claimed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | claimed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | claimed |
| CN-101282930-B | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS INC | 2012-10-24 | — | — | CN | disclosed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| CN-101282930-A | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS INC (KR) | 2008-10-08 | — | — | CN | disclosed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | MTNR1A 4823/4885APP 1687/4885BACE1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.